Medical Care
CHOP's Open-Source AI Tool for Noncommercial Use in Disease Analysis
2024-12-02
In a significant development, a groundbreaking artificial intelligence model developed at Children’s Hospital of Philadelphia is making waves. This model expedites the very first step of spatial omics data analysis, offering detailed insights into how diseases develop and progress at the cellular level. It holds the promise of advancing precise diagnostics and targeted treatments.

Unlock the Potential of AI in Spatial Omics

How the Model Works

The hospital's open-source AI tool, CelloType, is now accessible in a public repository for noncommercial use. Pediatric researchers developed this deep learning-enhanced biomedical imaging model to speed up the identification and classification of cells in tissue images. It has been tested across a wide range of complex diseases such as cancer and chronic kidney disease.

CelloType is programmed to enhance accuracy in cell detection, segmentation, and classification. It is highly efficient in handling large-scale tasks like natural language processing and image analysis. While it requires training for segmentation and classification tasks, it learns patterns and makes predictions or classifications faster than previous approaches.

Comparing with Other Models

The researchers compared CelloType's performance against models that segment multiplexed tissue images, including Mesmer and Cellpose2. In their report published in Nature Methods, they detailed the results of this National Institutes of Cancer-funded research. "Unlike the traditional two-stage approach of segmentation followed by classification, CelloType adopts a multitask learning strategy that integrates these tasks, simultaneously enhancing the performance of both," they stated.

Conventional segmentation methods face challenges with certain cell types that are either large or of irregular shape. CelloType, which utilizes transformer-based deep learning and automates the analysis of high-dimensional data, better captures the complex relationships and context in tissue samples.

The Larger Trend in Spatial Omics

There is a growing need in the field of spatial omics for more sophisticated computational tools for data analysis. Recent advancements have enabled the analysis of intact tissues at the cellular level, providing unparalleled insights into the link between cellular architecture and the functionality of various tissues and organs.

Using AI to improve the understanding of biomedical images is not only beneficial for clinicians in treating patients but also enhances patient access to advanced imaging. It even has the potential to predict diseases like cancer. As a result, health systems are increasingly embracing AI imaging tools.

For example, in Norway and Denmark, researchers are using mammography images in national breast cancer-screening programs to predict diagnoses. Stamford Health's Heart & Vascular Institute announced in October that its patients will automatically receive coronary artery disease screening during non-contrast chest CT scans when their future risk indicators are elevated. "This tool enhances our ability to detect early signs of cardiovascular disease and ensures that patients receive the follow-up care they need to prevent serious health outcomes," said Dr. David Hsi, chief of cardiology and the institute's co-director.

The Impact on Healthcare

One chief medical officer and pediatrics professor believes that with the help of AI and machine learning, healthcare providers can make a significant difference in treating patients with complex diseases. "Personalized genetic and epigenetic information can help tailor many medications to specific patients and diseases. All of these omics involve huge amounts of data that information technology can now analyze in exquisite detail and assess functionally through artificial intelligence and machine learning-derived algorithms," Dr. William Hay Jr., chief medical officer at Astarte Medical, told Healthcare IT News last year.

As Tan said in a statement, "We are just beginning to unlock the potential of this technology." The future holds great promise as this AI model continues to revolutionize spatial omics data analysis and its applications in healthcare.

GE HealthCare to Gain Full Control of Nihon Medi-Physics
2024-12-02
In a significant development in the healthcare industry, GE HealthCare has set its sights on taking full control of Nihon Medi-Physics. This Tokyo-based company is renowned for its production of diagnostic radiopharmaceuticals and molecular imaging agents. The journey towards this acquisition began when GE HealthCare and Sumitomo Chemical shared ownership of Nihon Medi-Physics down the middle. However, now GE HealthCare is all set to buy out the remaining 50% stake, with the deal expected to close by the end of March 2025.

Transforming the Molecular Imaging Landscape

As the third largest pharmaceutical market globally and among the leading countries in terms of the number of cyclotrons, Japan is on a trajectory to emerge as a leader in the $7 billion molecular imaging global market. Kevin O’Neill, president and CEO of GE HealthCare’s pharmaceutical diagnostics segment, emphasizes this in a statement. Nihon Medi-Physics will play a crucial role in this journey, bringing its extensive expertise and scale to global innovators. This will not only facilitate the introduction of novel products to the Japanese market but also extend its reach to other Asian markets. By strengthening GE HealthCare's precision care strategy in Asia and leveraging its existing footprint in Japan, where contrast media and medical devices are widely used for imaging procedures, the company is poised to make a significant impact.

The History and Present of Nihon Medi-Physics

Nihon Medi-Physics was founded in 1973 and has since established a strong presence. It currently maintains 13 manufacturing facilities, producing a diverse portfolio of radiotracer products. Products like Vizamyl, DaTSCAN, and Myoview, which are used in various imaging exams across neurology, cardiology, and oncology, have become integral to the healthcare landscape. In 2023, the company generated 28.2 billion yen, approximately $183 million U.S. This financial success is a testament to its commitment to quality and innovation.

The Significance of the Acquisition for Sumitomo Chemical

Sumitomo Chemical has had a 50-year relationship with Nihon Medi-Physics. Executive VP Hiroshi Ueda highlights the importance of this partnership in ensuring that patients in Japan can benefit from access to molecular imaging. In an industry witnessing exciting developments, Sumitomo Chemical believes that GE HealthCare is the ideal owner to enable Nihon Medi-Physics to continue its successful growth journey. The expected addition of about 30 billion yen to Sumitomo Chemical's operating income, approximately $200 million U.S., further underscores the significance of this deal.

The Impact on GE HealthCare's Global Strategy

GE HealthCare originally acquired its 50% ownership of Nihon Medi-Physics in 2004 through the purchase of the U.K. radiopharma manufacturer Amersham. This acquisition has now paved the way for full control, allowing GE HealthCare to integrate Nihon Medi-Physics more seamlessly into its global operations. With the company's extensive resources and expertise, Nihon Medi-Physics is set to reach new heights, contributing to GE HealthCare's continued growth and leadership in the healthcare sector. The combination of GE HealthCare's global reach and Nihon Medi-Physics' local expertise is expected to create a powerful synergy, benefiting patients and healthcare providers alike.
See More
GE HealthCare Buys Remaining 50% Stake in Nihon Medi-Physics from Sumitomo Chemical
2024-12-02
GE HealthCare's significant acquisition of Nihon Medi-Physics (NMP) from Sumitomo Chemical is set to reshape the medical imaging landscape. This move gives GE HealthCare full ownership of NMP, a company with a rich history and expertise in medical imaging. With a 50% stake since 2004, GE is now poised to leverage NMP's capabilities to drive growth in the molecular imaging market.

Unlock the Potential of Medical Imaging with GE HealthCare's Acquisition

Acquisition Details

GE HealthCare's acquisition of NMP marks a major milestone. Since acquiring Amersham plc in 2004 for $9.5 billion, GE has held a 50% stake in NMP. This acquisition allows NMP to expand its expertise in developing and manufacturing radiopharmaceuticals used in SPECT and PET molecular imaging procedures. Its product line includes GE HealthCare radiopharmaceuticals used in various clinical procedures. NMP also focuses on research and development, including nonclinical and clinical development of radiotracers and theranostics research.

NMP's 13 manufacturing facilities provide a solid foundation for its growth. With this acquisition, GE HealthCare is well-positioned to strengthen its precision care strategy in Asia and expand its footprint in Japan, where its contrast media and medical devices are widely used.

Hiroshi Ueda, executive vice president of Sumitomo Chemical, expressed pride in the 50-year relationship with NMP and its partnership with GE HealthCare. He believes that GE HealthCare is the best owner to enable NMP's continued growth.

Innovations at RSNA 2024

GE HealthCare exhibited over 40 innovations at the Radiological Society of North America's (RSNA) 2024 Annual Meeting in Chicago. Workflow efficiency technologies like Clarify DL, an AI-powered bone-image reconstruction algorithm, enhance bone SPECT image quality and increase diagnostic confidence. Command Lite by IONIC Health enables radiology staff to focus on patient care while accessing remote collaboration and scan assistance.

In November, GE HealthCare announced the Pristina Via mammography system, designed to improve the screening experience for technologists and patients. It provides a suite of tools to balance diagnostic accuracy and fast-paced workflows for more patient-centered breast care.

GE HealthCare also announced additional clinical applications for the OEC 3D mobile CBCT C-arm portfolio to enable precise and effective imaging during endoscopic bronchoscopy procedures.

See More